The round was led by Bessemer Venture Partners, with participation from TLV Partners, Vintage Investment Partners and Saras Capital, as well as executives from Meta, OpenAI and Wiz. Over a dozen pharma and biotech customers now use Converge's solutions for target discovery, antibody design, and protein manufacturing optimization.

Converge Bio is an AI platform that enables biotech and pharmaceutical companies to accelerate drug discovery and development. Founded in 2024, Converge's 40-person team has deep expertise in machine learning, computational biology, and drug development; about half hold advanced degrees in related fields. CEO Dov Gertz developed a machine-learning method for discovering novel CRISPR systems, leading to a U.S.-licensed patent and a scientific publication in collaboration with Nobel laureate Jennifer Doudna. CSO Iddo Weiner holds a PhD in Bioinformatics and Biomedical Engineering, and has led the development of two drug programs through positive Phase 2 clinical readouts. CTO Oded Kalev previously led cybersecurity AI teams and has advised U.S. government agencies on large-scale generative AI applications.